BioCardia

BioCardia Net Debt/FCF

The Net Debt to Free Cash Flow Ratio of BioCardia (BCDA) as of Nov 20, 2026 is 0.26. In the previous year, Net Debt to Free Cash Flow Ratio was 0.18 — a change of 49.56% (higher).

Net Debt/FCF

0.26

YoY

49.56%

Last updated:

Net Debt to Free Cash Flow Ratio of BioCardia is 2025 0.26 . Net Debt to Free Cash Flow Ratio of BioCardia was 2024 0.18 . It decreases by 49.56% higher compared to the previous year.

The BioCardia Net Debt/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt/FCF
Date
Net Debt/FCF
Jan 1, 2017
1.43 USD
Jan 1, 2019
0.46 USD
Jan 1, 2020
1.68 USD
Jan 1, 2021
1.05 USD
Jan 1, 2022
0.54 USD
Jan 1, 2023
-0.02 USD
Jan 1, 2024
0.18 USD
Jan 1, 2025
0.26 USD
The BioCardia Net Debt/FCF history
YEARNet Debt/FCFYoY
0.26+49.56%
0.18-932.76%
-0.02-103.94%
0.54-48.64%
1.05-37.45%
1.68+262.30%
0.46-67.53%
1.43-61.33%
3.69-109.30%
-39.65+6.24%
-37.32—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioCardia Stock analysis

What does BioCardia do? BioCardia, Inc. generates revenue through its clinical-stage regenerative medicine portfolio, primarily focused on CardiAMP and CardiALLO cell therapies. The CardiAMP Cell Therapy System is in Phase III trials for ischemic systolic heart failure, targeting healthcare providers and clinical trial sponsors seeking advanced treatments for heart failure patients. CardiALLO, an allogeneic off-the-shelf mesenchymal stem cell product, is developed for broader therapeutic applications, appealing to hospitals and research institutions requiring ready-to-use regenerative solutions. The company also monetizes the Helix Biotherapeutic Delivery System and Morph Deflectable Guide and Sheaths Products, which serve as complementary tools for medical professionals during therapeutic procedures. CardiAMP and CardiALLO are positioned as innovative therapeutic candidates targeting heart failure and regenerative medicine segments, with CardiAMP advancing toward potential commercialization in late-stage trials. The Helix Biotherapeutic Delivery System and Morph Deflectable Guide and Sheaths Products cater to interventional cardiology and surgical markets, providing specialized equipment for clinicians. BioCardia's revenue streams are derived from partnerships with clinical trial sponsors and direct sales of medical devices to healthcare facilities, focusing on cardiovascular and regenerative medicine applications. The company's business model relies on developing and commercializing cell therapies and medical devices, with CardiAMP leading the portfolio in late-stage development. CardiALLO serves as a complementary allogeneic product, while the Helix and Morph products support procedural needs in cardiology. Revenue is anticipated from future commercialization of CardiAMP post-trial success and from ongoing sales of the Helix and Morph systems to medical institutions. BioCardia is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioCardia stock

Net Debt to Free Cash Flow Ratio of BioCardia is 0.26 in 2025.

Net Debt to Free Cash Flow Ratio of BioCardia changed from 0.18 to 0.26, representing a 49.56% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to Free Cash Flow Ratio BioCardia since 2006 – with annual values, charts, and detailed analysis.

Net Debt/FCF indicates how many years it would take to repay net debt using free cash flow. Lower ratios suggest faster deleveraging potential.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to Free Cash Flow Ratio's BioCardia with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — BioCardia

All Key Metrics — BioCardia